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Pretransplant Donor-specific IFNγ ELISPOT as a 
Predictor of Graft Rejection: A Diagnostic Test 
Accuracy Meta-analysis
Nuria Montero, MD, PhD,1 Samira Farouk, MD,2 Ilaria Gandolfini, MD,3 Elena Crespo, PhD,4 Marta Jarque, MS,4 
Maria Meneghini, MD,4 Alba Torija, MS,4 Umberto Maggiore, MD, PhD,3 Paolo Cravedi, MD, PhD,2  
and Oriol Bestard, MD, PhD1,4
During the last decades, the refinement of prekidney transplant risk immune monitoring and evaluation 
of the humoral arm of adaptive immunity has led to more 
effective kidney allocation and a dramatic reduction 
of posttransplant acute antibody-mediated rejection.1-3 
However, T  cell-mediated rejection (TCMR) unpredictably 
occurs, as no immune-risk stratification of cellular sensiti-
zation before transplantation is available in current clinical 
Kidney Transplantation
Background. Pretransplant interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) has been proposed as a tool 
to quantify alloreactive memory T cells and estimate the risk of acute rejection (AR) after kidney transplantation, but stud-
ies have been inconclusive so far. We performed a meta-analysis to evaluate the association between pretransplant IFN-γ 
ELISPOT and AR and assess its predictive accuracy at the individual level. Methods. We estimated the pooled summary 
of odds ratio for AR and the joined sensitivity and specificity for predicting AR using random-effects and hierarchical summary 
receiver-operating characteristic models. We used meta-regression models with the Monte Carlo permutation method to 
adjust for multiple tests to explain sensitivity and specificity heterogeneity across studies. The meta-analytic estimates of sen-
sitivity and specificity were used to calculate positive and negative predictive values across studies. Results. The analysis 
included 12 studies and 1181 patients. IFN-γ ELISPOT was significantly associated with increased AR risk (odds ratio: 3.29; 
95% confidence interval (CI), 2.34-4.60); hierarchical summary receiver operating characteristic jointly estimated sensitivity 
and specificity values were 64.9% (95% CI, 53.7%-74.6%) and 65.8% (95% CI, 57.4%-73.5%), respectively, with moderate 
heterogeneity across studies. After adjusting for multiple testing, meta-regression models showed that thymoglobulin induc-
tion, recipient black ethnicity, living versus deceased donors, and geographical location did not affect sensitivity or specificity. 
Because of the varying AR incidence of the studies, positive and negative predictive values ranged between 16%–60% and 
70%–95%, respectively. Conclusions. Pretransplant IFN-γ ELISPOT is significantly associated with increased risk of AR 
but provides suboptimal predictive ability at an individual level. Prospective randomized clinical trials are warranted.
(Transplantation Direct 2019;5:e451; doi: 10.1097/TXD.0000000000000886. Published online 25 April, 2019.)
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practice. Indeed, immunosuppressive protocols after kidney 
transplantation are generally adjusted on empirical bases 
and on a functional or histological evaluation of the allo-
graft and/or signs of drug toxicity or infection.4 As a result, 
there are patients who are likely to receive too much or 
too little immunosuppression—exposing them to higher 
rates of infection, malignancy and drug toxicity, or con-
versely, to increased risk of acute and chronic graft rejec-
tion. Therefore, developing reliable biomarkers of antidonor 
T-cell alloimmune reactivity is crucial to individualize immu-
nosuppressive therapy ultimately aimed at reducing allograft 
rejection risk, while minimizing adverse effects associated 
with over-immunosuppression.5
The interferon-γ enzyme-linked immunospot (IFN-γ 
ELISPOT) is an immune assay that has been developed and 
standardized in the field of transplantation as a way to func-
tionally measure the number of circulating memory T cells 
with donor antigen reactivity.6,7 While a number of single-
center studies have reported a close association between posi-
tive pretransplant IFN-γ ELISPOT and increased risk of acute 
rejection (AR), particularly TCMR, and poor graft function at 
6 and 12 months after transplantation,8-10 other studies have 
failed to identify such associations.11 Due to the high vari-
ability in patient characteristics and treatments across studies, 
we hypothesized that the IFN-γ ELISPOT performs differently 
in various patient populations and settings. Moreover, most 
published studies lack an acceptable balance regarding the 
predictive accuracy, which is a key for a biomarker to be used 
in the clinical practice.
To overcome these issues, we performed a meta-analysis of 
aggregate data from all published studies (including almost 
1200 kidney transplant patients) evaluating the predictive per-
formance of the pretransplant donor-specific IFN-γ ELISPOT 
as the most promising immune biomarker assessing the risk 
of TCMR in kidney transplant recipients. Our primary objec-
tive was to provide precise estimates of the predictive value 
of the pretransplant IFN-γ ELISPOT for AR at the individual 
level, taking into account all potential sources of heteroge-




We performed a systematic literature search using the 
Cochrane Central Library, MEDLINE, and EMBASE data-
bases up to October 2016 using a predefined algorithm (Table 
S1, SDC, http://links.lww.com/TXD/A207). Abstracts from 
proceedings of major conferences, International Clinical 
Trials Registry Platform Search Portal, and ClinicalTrials.
gov were also searched. References included in pertinent 
systematic reviews were then screened. Studies were deemed 
eligible if they measured prekidney transplant donor-spe-
cific IFN-γ ELISPOT in patients who received a living- or 
deceased-donor kidney transplant alone. We excluded the 
studies if immunosuppression was modified on the basis of 
ELISPOT results.12 During screening, only articles written 
in English were included to prevent any misinterpretation 
of data. Study outcomes were not included as a part of the 
eligibility criteria.
All references were screened by 2 independent reviewers 
(S.F.  and I.G.). If any discrepancies occurred, 2 additional 
reviewers were consulted (N.M. and O.B.). The study review-
ers also examined reference lists of clinical practice guidelines, 
review articles, and relevant studies to identify missing arti-
cles and sent e-mails to investigators known to be involved 
in previous studies seeking information about unpublished or 
incomplete trials.
The protocol of this systematic review is published in the 
PROSPERO register (#CRD42018116382).
Data Extraction, Outcomes, and Quality Assessment
Data extraction was independently performed by 3 review-
ers (N.M., S.F., and I.G.) using standard data extraction forms. 
Reviewers were not blinded to authors, institutions, or arti-
cle journals. If any discrepancies occurred, a consensus was 
reached after consulting a fourth investigator (O.B.).
Data extraction included the following characteristics of 
the studies: author’s name, year of publication, number of 
included patients, duration of follow-up, donor and recipi-
ent demographics, and clinical characteristics. Outcomes were 
identified in the studies’ text or tables. Data regarding death 
and graft loss were extracted from survival curves when nec-
essary. The primary outcome was the incidence of AR (both 
clinically suspected and biopsy proven). Secondary outcomes 
were graft function (defined by estimated glomerular filtra-
tion rate [eGFR] and serum creatinine) and patient and graft 
survival.
Risk of Bias Assessment/Quality Assessment
We used Hayden criteria to estimate the bias of the included 
studies.13
This tool evaluates 6 domains as follows:
 1. Study participation: the study sample adequately repre-
sents the population of interest.
 2. Study attrition: the study data available (ie, participants not 
lost to follow-up) adequately represent the study sample.
 3. Prognostic factor (PF) measurement: the PF is measured in 
a similar way for all participants.
 4. Outcome measurement: the outcome of interest is meas-
ured in a similar way for all participants.
 5. Study confounding: important potential confounding fac-
tors are appropriately accounted for.
 6. Statistical analysis and reporting: the statistical analysis is 
appropriate, and all primary outcomes are reported.
Data Synthesis and Analysis
We presented the results from all studies using the origi-
nal manufacturer scale for test interpretation. The IFN-γ 
ELISPOT value cutoff to define positivity in the majority of 
studies was 25 spots/3×105 peripheral blood mononuclear 
cells (PBMCs),9,11,12,14-18 though in 2 studies the cutoff was 
defined as 12 spots/3×105 PBMCs.19,20 In 1 study,18 we evalu-
ated a cutoff of 25 spots/3×105 PBMCs to homogenize all 
study data, as the cut-off was not explicitly defined.
We followed the Meta-analyses of Observational Studies in 
Epidemiology guidelines to report this systematic review and 
used Stata SE Release 15 (StataCorp, College Station, TX) for 
all analyses.21
We evaluated the association between pretransplant donor-
specific IFN-γ ELISPOT and AR by calculating the odds ratio 
(OR) via random-effects meta-analysis. To overcome the 
presence of 0 cells in some of the 2×2 contingency tables, we 
added a small constant ε = 0.5 to all cells.22
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To examine the predictive accuracy of pretransplant IFN-γ  
ELISPOT at the individual level, we performed a random-
effects meta-analysis on sensitivity and specificity. Sensitivity 
represents the proportion of IFN-γ ELISPOT-positive patients 
who eventually developed AR, whereas specificity is the 
proportion of IFN-γ ELISPOT-negative patients who were 
AR free. To provide a joint pooled estimate of sensitivity and 
specificity which accounts for the correlation between the 2 
parameters, we fitted a hierarchical summary receiver operat-
ing characteristic (ROC) model using the user-written Stata 
command metandi.23,24 Using the command metandplot, we 
also plotted the model-fitted results, a summary ROC curve, 
a 95% confidence region, and a 95% prediction region (ie, 
confidence region for a forecast in a future study of the sum-
mary operating point of sensitivity and specificity).23,24 Besides 
calculating the meta-analytic estimates of joined sensitivity 
and specificity, we also calculated the meta-analytic positive 
and negative likelihood ratios. These ratios can be interpreted 
as follows: a completely nonpredictive assay is reflected by a 
positive and negative likelihood ratio of 1; a slightly, moder-
ately, and highly predictive assay is reflected by a positive like-
lihood ratio of above 2, 5, and 10 and by a negative likelihood 
ratio of below 0.5, 0.2, and 0.1, respectively.25
In an attempt to explain the reasons for heterogeneity across 
study findings concerning sensitivity and specificity and to iden-
tify patient categories in which pretransplant IFN-γ ELISPOT 
could be most useful, we additionally fitted metaregression 
models using the user-written Stata metareg command.26 
These models were designed to examine to what extent sen-
sitivity and specificity of IFN-γ ELSPOT could be affected by 
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the type of induction therapy used (independent variable = % 
of thymoglobulin use), by ethnicity (% of African American 
recipients), by living- versus deceased-donor kidney trans-
plantation (% of living donors), by era of study publication 
(year as continuous variable), and by geographical location 
of the study (indicator variable for North America, Asia, or 
Europe). To avoid inflating the rate of false-positive findings 
because of multiple testing, we referred to Monte Carlo per-
mutation tests rather than the default nominal P values when 
declaring statistical significance (ie, 2-tailed, P < 0.05) using the 
methodology proposed by Higgins and Thompson.27 However, 
in the meta-regression plots, we reported default nominal P val-
ues calculated by the default Knapp-Hartung variance estima-
tor and associated t tests.28 For the purpose of meta-regression 
analyses, sensitivity and specificity were logit transformed. 
Sensitivity analyses were performed after the exclusion of the 
study published by our group.12 In this study, the type of immu-
nosuppression was given according to the pretransplant IFN-γ 
ELSPOT. To see whether the inclusion of a study in which 
some patients underwent complete tacrolimus withdrawal 
might have accounted for inconsistencies between study find-
ings, the analysis was repeated without this study (Figure S1, 
SDC, http://links.lww.com/TXD/A207).
Heterogeneity was analyzed using a chi-squared test on 
N−1 degrees of freedom, with an alpha of 0.05 used for sta-
tistical significance and the I2 test.27 The I2 statistic describes 
the percentage of total variation across studies that is due to 
heterogeneity rather than chance; I2 values of 25%, 50%, and 
75% are indicative of low, moderate, and extreme heterogene-
ity, respectively.27 The pooled meta-analytic estimates should 
be interpreted with caution whenever I2 is >50%. An I2 >50% 
indicates that most of the observed differences between the 
study findings on the relation between IFN-γ ELISPOT and 
AR may be due to true underlying inconsistencies between 
study results rather than random variation.
Finally, the meta-analytic estimates of joined sensitivity 
and specificity were used to calculate positive predictive value 
(PPV) and negative predictive value (NPV) in each study pop-
ulation from the selected studies. Because PPV and NPV are 
functions not only of IFN-γ ELISPOT sensitivity and specific-
ity but also of the population-specific incidence of AR, we did 
not report them as fixed numbers but rather as numbers vary-
ing with pretest risk of AR.
Similar analyses were performed to examine the second-
ary outcomes including the association between pretransplant 
IFN-γ ELISPOT and graft function, graft survival, and patient 
survival. We had planned to similarly analyze de novo DSA, 
but reported data in the studies were insufficient.
RESULTS
Literature Search Results and Study Characteristics
A total of 584 potentially relevant citations were identified 
(EMBASE: 368; CENTRAL: 15; MEDLINE: 201). After the 
review of the titles and abstracts and the removal of dupli-
cates, a total of 353 potentially eligible articles were identi-
fied. We excluded 335 studies for the following reasons: index 
test not evaluated (195 studies); insufficient data (lack of suf-
ficient data to derive 2 × 2 tables or assess test performance 
in participants) or duplicate data (8 studies); different target 
population (hemodialysis patients, animal models) (59 stud-
ies); or studies using pretransplant IFN-γ ELISPOT for treat-
ment decision purposes (1 study).12 The same procedure was 
followed for editorials, reviews, or comments (73 studies). We 
ultimately included 12 studies in our analyses (19 reports) 
with 1181 patients.10,11,14-20,29-38 Figure 1 shows the flow chart 
FIGURE 2. Forest plot of analysis acute rejection (AR).
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for study selection. All studies reported pretransplant donor-
specific IFN-γ ELISPOT data and included a total of 1238 
kidney transplant patients. The characteristics of the included 
studies are presented in Table 1.
Risk of Bias
To evaluate the risk of bias, we followed the Hayden cri-
teria.13 All the bias domains for all the studies are presented 
in Table 2.
In general, there was an overall low risk of bias in all the 
domains. The relationship between the PF and outcome may 
have differed between participants and eligible nonpartici-
pants in 2 studies. In the study by Augustine,14 there was no 
information about the sampling frame and recruitment. The 
authors of the study by Kim19 did not specify the place of 
recruitment. We found a high risk of bias in 1 study, as the 
authors did not give any information about the period and 
place of recruitment20 and in another29 because there was an 
early interruption with high incidence of rejections in the tac-
rolimus withdrawal arm. This reason made us consider also a 
moderate risk of bias due to presence of differences between 
participants who completed the study and those who did not.
The methods and setting of measurement of the PF in our 
meta-analysis (pretransplant IFN-γ ELISPOT) were not the 
same for all study participants, and that brought a moderate 
risk of bias in 3 studies.11,12,16 The method of imputation used 
for missing PF data was not correct and gave another study a 
high risk of bias.11 The outcome measurement was of low risk 
of bias for all studies except for 111 that presents a high risk 
of bias in the method and setting of outcome measurement, 
which was not the same for all study participants.
Acute Rejection
Out of the 1181 included kidney transplant recipients, 209 
(18%) developed AR, with an incidence ranging between 8% 
and 44% in each study. Pretransplant donor-specific IFN-
γ ELISPOT was positive in 512 (43%) of the patients and 
ranged between 25% and 88% in each study.
Positive pretransplant IFN-γ ELISPOT was associated 
with a significantly high risk of AR (odds ratio 3.29; 95% 
confidence interval (CI), 2.34-4.60) (Figure 2 and Figure S1, 
SDC, http://links.lww.com/TXD/A207). Pooled sensitivity 
and specificity for AR, jointly estimated via the hierarchical 
summary ROC model, were 64.9% (95% CI, 53.7%-74.6%) 
and 65.8% (95% CI, 57.3%-73.5%). The joint sensitivity and 
specificity estimates resulted in a positive likelihood ratio and 
a negative likelihood ratio of 1.90 (95% CI, 1.58-2.28) and 
0.53 (95% CI, 0.42-0.68), respectively. Because the values of 
positive likelihood ratio below 2.0 and negative likelihood 
ratio above 0.5 are generally regarded as reflecting limited 
prognostic ability, our findings indicate that the added value 
of pretransplant IFN-γ ELISPOT to predict AR at the individ-
ual level is at the edge of being significant.39 Notably, results 
of the joined meta-analysis of sensitivity and specificity and 
the associated summary ROC curve showed a certain degree 
of heterogeneity across studies (Figure 3 and Figure S2, SDC, 
http://links.lww.com/TXD/A207).
To test whether differences across studies concerning sensi-
tivity and specificity could be explained by differences in the 
characteristics of the study populations such as the type of 
induction therapy, ethnicity, and geographical area, and also 
to identify patient categories in which pretransplant IFN-γ 
ELISPOT could be most useful, we performed metaregression 
analyses (Figure 4 and Figures S3 and S4, SDC, http://links.
lww.com/TXD/A207). After adjusting for multiple testing 
to prevent spurious findings, metaregression models did not 
show evidence that thymoglobulin induction, recipient black 
ethnicity, living versus deceased donors, or geographical loca-
tion affected sensitivity or specificity, but publication year was 
the only variable with a significant inverse association with 
specificity (P = 0.021).
We used the joint meta-analytic estimates of sensitivity and 
specificity to calculate PPV and NPV in each study popula-
tion from the 12 selected studies. As a consequence of the fact 
that the study populations differed greatly with regard to the 
incidence of AR, PPV was rather low, ranging between 16% 
FIGURE 3. HSROC plot of analysis of acute rejection, namely joined 
meta-analysis of sensitivity and specificity and associated summary 
ROC curve concerning the predictive power of IFNγ ELISPOT for 
acute rejection, based on the fitted hierarchical logistic regression 
model. The graph shows the pooled summaries, together with circles 
showing the individual study estimates; the solid line represents 
the estimate of the summary ROC curve, and the square symbol 
represents a summary value for sensitivity and specificity of  64.9% 
(95% CI, 53.7-74.6) and 65.8% (95% CI: 57.4-73.5), respectively. 
The dotted green line represents the 95% confidence region for the 
summary operating point (ie, every sensitivity/specificity value lying 
within the region delimited by the green line must be regarded as not 
significantly different from our pooled estimate, at 5% significance 
level). The dotted orange line represents the 95% prediction region 
(confidence region for a forecast of the true sensitivity and specificity 
in a future study). The shape of the prediction region is dependent 
on the assumption of a bivariate normal distribution for the random 
effects included in the statistical model. It should therefore not be 
overinterpreted; it is intended to give a visual representation of the 
extent of between-study heterogeneity. CI, confidence interval; 
HSROC, hierarchical summary receiver-operating characteristic; IFN-
γ, interferon-γ enzyme-linked immunospot; ROC, receiver operating 
characteristic.
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and 60%, whereas NPV was significantly higher and ranged 
between 70% and 95% (Figure 5 and Table 3), respectively. 
In studies where the risk of AR was 16% or lower—which is 
the case of most transplant centers nowadays—a negative pre-
transplant IFN-γ ELISPOT implied an NPV of 91% or higher 
(ie, a predicted risk of AR of 9% or lower).
Graft Function
Six- and 12-month serum creatinine and eGFR were similar 
between patients with positive or negative pretransplant IFN-γ  
ELISPOT (weighted mean differences for serum creatinine at 
6 and 12 months were as follows: 1.24 mg/dL [−0.72, 3.2], 
P = 0.22 and 0.38 mg/dL [−0.27, 1.04], P = 0.25, respectively; 
FIGURE 4. Relationship between sensitivity or specificity and the prevalence of thymoglobulin use (A), the prevalence of African Americans (AAs) 
(B), the publication year (C) of each study, estimated by random-effects meta-analysis (ie, metaregression). The size of the circles is proportional 
to the weight of each study, which is inversely proportional to the study variance. The variance is calculated as the sum of the within- and the 
between-study variances; therefore, it is not only dependent on the size of the study population. Sensitivity and specificity values on y-axis are 
obtained from backtransformation of the logit values; therefore, the scale of the y-axis is not linear. At the bottom of the graph are reported 
predictions based on the fitted model, for example, what would have happened to sensitivity or specificity if the prevalence of thymoglobulin use 
in the study population had been 0% or 100% (A); if the prevalence of AA had been 0% or 100% (B); and if the publication year of the studies had 
been 2005 for all studies or 2015 for all studies (C). Each figure reports the nominal P value using the default Knapp-Hartung variance estimator, 
testing that the regression slope is significantly different from zero. However, statistical inference mentioned in the text was not based on those 
nominal P values but rather on adjustment for multiple testing using Monte Carlo permutation test based on the methodology proposed by 
Higgins and Thompson. The I2 represents the proportion of the variance between studies, which is due to unmeasured heterogeneity between 
studies rather than chance or difference in the variable on the x-axis of the plot. IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot.
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weighted mean difference for eGFR at 6 and 12 months were 
as follows: −0.97 [−2.07, 0.13], P = 0.08 and −0.49 [−1.27, 
0.28], P = 0.21, respectively). However, there was a high het-
erogeneity between the 2 studies meta-analyzed (I2 > 75%) 
(Figures 6 and 7).
Graft and Patient Survival
The very limited number of studies assessing the impact 
of the pretransplant IFN-γ ELISPOT on graft loss or patient 
survival did not allow us to perform a meta-analysis on these 
outcomes. The pooled sensitivity and specificity of pretrans-
plant IFN-γ ELISPOT for both 1-year patient and graft sur-
vival prediction are shown in Figures 8 and 9.
DISCUSSION
To the best of our knowledge, this is the first meta-analysis 
to date investigating the association between pretransplant 
donor-specific IFN-γ ELISPOT and graft outcomes in kid-
ney transplant recipients. The data show that pretransplant 
donor-specific IFN-γ ELISPOT is significantly associated with 
a higher risk of AR. Notably, and although the predictive val-
ues of the assay vary depending on the incidence of AR in each 
study, the NPV of this assay is consistently high (ie, >90%), 
particularly in low-risk populations (ie, with AR risk ≤16%). 
Moreover, and based on our regression analyses on aggregate 
data, the performance of the assay in predicting graft out-
comes seems not to be strongly affected by study population 
characteristics. We found an apparent trend of specificity to 
FIGURE 5. Positive and negative predictive values of IFNγ ELISPOT as a function of the incidence of AR in the study population. Because 
positive and negative predictive values are not fixed numbers but rather numbers varying with the incidence of AR in the study population, the 
plot shows on the y-axis how positive or negative predictive values (ie, posttest AR risk) change according to different values of the incidence of 
AR in the study population (ie, pretest AR risk) reported on x-axis. To visualize how pretest probability changes with the result of IFN-γ ELISPOT, 
draw a vertical line from a chosen pretest probability of AR on the x-axis until it hits the red curve if IFN-γ ELISPOT is positive, or the green curve 
if IFN-γ ELISPOT is negative, and read the resulting posttest probability of AR on the y-axis. Cross-marks and associated labels represent the 
positive and negative predictive values that would result from each study, based on the study-specific incidence of AR of and the overall joined 
meta-analytic estimate of sensitivity and specificity. AR, acute rejection; IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot.
TABLE 3.
Positive and negative predictive values of acute rejection
Author AR incidence PPV NPV
Hricik et al11,29 0.09 0.16 0.95
Gandolfini et al31 0.09 0.16 0.95
Kim et al19 0.12 0.21 0.93
Crespo et al17 0.16 0.27 0.91
Augustine et al16 0.19 0.31 0.89
Augustine et al15 0.22 0.34 0.87
Hricik et al30 0.22 0.34 0.87
Kim et al20 0.26 0.39 0.85
Crespo et al10 0.30 0.45 0.81
Augustine et al14 0.31 0.46 0.81
Nickel et al18 0.39 0.54 0.75
Hricik et al11,29 0.44 0.60 0.70
AR, acute rejection; NPV, negative predictive value; PPV, positive predictive value.
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decrease in the years, although we could not infer whether this 
association was related to unmeasured confounding variables 
or simply represented a random finding.
Today, the assessment of the immunologic risk in organ 
transplant recipients before transplantation is exclusively 
done by the assessment of donor/recipient HLA mismatch and 
the presence of preformed circulating anti-HLA antibodies,3 
with the assumption that the humoral allosensitization also 
illustrates the allospecific cellular immune response. However, 
it is well known that cellular memory may occur without 
humoral activation and is a key factor in initiating and medi-
ating allograft rejection.40-43 In fact, experimental studies in 
mice have shown that alloreactive memory T cells play a 
major pathogenic role in allograft rejection, therefore measur-
ing these cells in a functional manner has been proposed as 
a strategy to estimate the risk of AR, especially TCMR. The 
IFN-γ ELISPOT has been developed to measure the frequency 
of alloreactive memory IFN-γ-producing T cells at the single 
cell level.44,45 While initial studies showed a clear association 
between pretransplant IFN-γ ELISPOT positivity and risk of 
AR,8,18 subsequent larger studies challenged this association, 
especially in subjects receiving T-cell-depleting induction ther-
apy with thymoglobulin.10-12
Overall, the present meta-analysis confirms a significant 
association between pretransplant donor-specific IFN-γ 
ELISPOT and higher risk of AR, particularly among those 
patients not receiving T-cell-depleting induction therapy. 
Though the accuracy to predict AR at the individual level 
is suboptimal, the high NPV (>90%) of this assay suggests 
that it could be used to identify patients at low risk of AR. 
Therefore, pretransplant donor-specific IFN-γ ELISPOT 
seems to represent an important tool to measure baseline cel-
lular risk stratification in kidney transplant recipients before 
transplant surgery and eventually allow immunosuppressive 
FIGURE 6. Forest plot of serum creatinine (mg/dL) at 6 (A) and 12 months (B). CI, confidence interval; SD, standard deviation.
FIGURE 7. Forest plot of eGFR at 6 (A) and 12 months (B). CI, confidence interval; eGFR, estimated glomerular filtration rate; SD, standard 
deviation.
FIGURE 8. Forest plot of graft loss censored for death at 1 year. CI, confidence interval.
FIGURE 9. Forest plot of analysis of all causes of death at 1 year. CI, confidence interval.
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therapy titration accordingly. However, additional biomark-
ers need to be developed and optimized to better estimate the 
immunological risk of subjects at the time of kidney trans-
plant. In this regard, as calcineurin inhibitors (CNI) are a 
key to effectively inhibiting T-cell activation and prolifera-
tion, markers accurately identifying patients with suboptimal 
tacrolimus pharmacokinetics could potentially add value for 
better patient T-cell immune risk stratification. Likewise, the 
value of this assay in patients receiving CNI-free immunosup-
pressive strategies such as costimulation blockade-based regi-
mens needs further investigation.
Our meta-analysis focused on pretransplant donor-spe-
cific IFN-γ ELISPOT. Only few studies addressed the util-
ity of serial ELISPOT measurements to detect subclinical 
AR, predict development of DSA, or graft dysfunction. Data 
from a prospective cohort study indicate that posttrans-
plant measurements of donor-reactive memory T cells by 
IFN-γ ELISPOT assay can identify, within kidney transplant 
patients with stable renal function, patients with minimal 
risk of having concurrent or future intragraft infiltrates.17 
Likewise, a nonrandomized interventional study showed 
that prospective evaluation of donor-specific T-cell sensitiza-
tion by IFN-γ ELISPOT may add important information on 
the alloimmune state of transplanted patients to be used in 
daily clinical practice.12 However, more studies are needed 
to address whether IFN-γ ELISPOT-driven immunosuppres-
sion provides better outcomes than standard, protocol-based 
clinical management. Two ongoing multicentric, randomized 
biomarker-driven trials are testing the utility of pretransplant 
IFN-γ ELISPOT (NCT02540395; NCT03465397) to person-
alize immunosuppression.
Limitations and Strengths
Our study should be interpreted in light of some limitations. 
Although we performed an exhaustive search of the literature 
for pretransplant donor-specific IFN-γ ELISPOT, publication 
bias cannot be ruled out. It is possible that smaller negative 
studies have not been published. Another important limitation 
is the variability in the standard operating procedure used for 
the IFN-γ ELISPOT. The fact that pretransplant ELISPOT has 
only been standardized across a relatively small number of 
centers6,7 may, at least in part, explain the heterogeneity across 
the different studies. Additional limitations include the rela-
tively low number of patients included in the analysis and the 
use of aggregate as opposed to individual level data; therefore, 
the statistical power may be inadequate for drawing definitive 
conclusions about the ability of pretransplant donor-specific 
IFN-γ ELISPOT to predict in different patient categories such 
as in patients receiving T-cell depletion induction or among 
those not receiving CNI-based immunosuppression.
The strengths of this analysis comprise the inclusion of a 
fairly large number of studies from different continents, which 
included a wide spectrum of patient categories. Nonetheless, 
our findings on test performance were reasonably consistent 
across the different studies.
CONCLUSIONS
In summary, this meta-analysis shows that in low-risk kid-
ney transplant populations a negative pretransplant donor-spe-
cific IFN-γ ELISPOT is associated with a very low probability 
of AR. Although the prediction of AR at the individual level 
is suboptimal, this assay could be used, in concert with oth-
ers, for treatment decision purposes in low-risk populations. 
Importantly, prospective, randomized, biomarker-driven trials 
using the IFN-γ ELISPOT assay are warranted. 
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